Chevron vs ExxonMobil
CVX and XOM side by side, both in petroleum refining. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CVX and XOM compare
ExxonMobil is the larger company, worth 1.6 times as much as Chevron ($688B against $427B).
On earnings, Chevron is cheaper: it trades at 20.7× trailing earnings, against 21.5× for ExxonMobil.
Chevron grew revenue faster over the last twelve months (10.2% versus 9.1% for ExxonMobil).
Chevron keeps more of each dollar of sales as profit, with a net margin of 9.6% compared with 8.9% at ExxonMobil.
Both pay dividends: Chevron yields 3.3% and ExxonMobil 1.8%.
Chevron scores higher on the StockData Score (12 against 11 for ExxonMobil), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CVX | XOM |
|---|---|---|
| Size and price | ||
| Market cap | $427B | $688B |
| Share price | $216.13 | $167.21 |
| Change, 1 year | 37.1% | 40.2% |
| Change, 5 years | 88.7% | 173% |
| Beta (5Y) | −0.73 | −0.83 |
| Employees | 4,645 | 58K |
| StockData Score | ||
| Total score | 12 (better) | 11 |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 20.7× (better) | 21.5× |
| P/S | 2.0× | 1.9× (better) |
| P/B | 2.2× (better) | 2.7× |
| EV/EBITDA | 7.6× (better) | 9.6× |
| P/FCF | 15.8× (better) | 22.5× |
| FCF yield | 6.3% (better) | 4.4% |
| Fair value | $179.95 | $124.03 |
| Margin of safety | −20.1% (better) | −34.8% |
| Growth | ||
| Revenue growth (TTM) | 10.2% (better) | 9.1% |
| Revenue growth, 5Y average | 14.8% (better) | 12.9% |
| Net income growth (TTM) | 50.1% (better) | 5.6% |
| EPS growth (TTM) | 34.6% (better) | 10.4% |
| Profitability | ||
| Gross margin | 45.4% | – |
| Net margin | 9.6% (better) | 8.9% |
| FCF margin | 12.5% (better) | 8.3% |
| Return on equity | 12.2% | 12.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.16 |
| Net debt / EBITDA | −0.17 | 0.42 (better) |
| Current ratio | 1.25 (better) | 1.13 |
| Altman Z-score | 3.49 | 4.39 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 3.3% (better) | 1.8% |
| Payout ratio | 67.3% | 52.6% |
| Years of dividend growth | 6 | 16 (better) |
| Dividend growth, 5Y average | 5.8% (better) | 2.8% |
| Buyback yield | 2.6% | 3.0% (better) |
| Shareholder yield | 5.9% (better) | 4.8% |
| Ownership | ||
| Held by institutions | 74.3% | 66.0% |
| Held by insiders | 0.34% | 0.00% |
| Insider net buying, 12 months | −$593M | – |
| Superinvestors holding | 4 (better) | 3 |
| Short interest, % of float | 1.3% | 1.1% |
Go deeper
- CVX stock overview
- CVX income statement
- CVX valuation and score
- XOM stock overview
- XOM income statement
- XOM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.